Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Ratanatharathorn, Voravit  [Clear All Filters]
Journal Article
Veeraputhiran M, Jain T, Cronin S, Al-Kadhimi Z, Abidi MH, Ayash L, Mellert K, Lum LG, Ratanatharathorn V, Uberti JP, et al. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant. J Clin Apher. 2014.
Modi D, Kim S, Surapaneni M, Ayash L, Alavi A, Ratanatharathorn V, Deol A, Uberti JP. R-BEAM versus Reduced Intensity Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2019.
Mehta RS, Ali H, Dai Y, Yao B, Overman B, Ratanatharathorn V, Gill S, Socié G, Anderson K, Cahn JYves, et al. A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplant. 2023.
Modi D, Chi J, Kim S, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Outcomes of Fludarabine, Melphalan and Total Body Irradiation as a Reduced Intensity Conditioning Regimen in Matched Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Outcomes of Flu-Mel-TBI. Transplant Cell Ther. 2021.
Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, et al. Long-term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. Biol Blood Marrow Transplant. 2014.
Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez H, Mineishi S, Kamishohara M, Mehta J, Nakamura Y, et al. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2016.
Albanyan O, Alkassis S, Kim S, Kin A, Alavi A, Ayash L, Ratanatharathorn V, Modi D, Uberti JP, Deol A. Impact of pre-transplant induction therapy on outcomes of patients who undergo autologous stem cell transplantation for mantle cell lymphoma in first complete remission. Hematol Oncol Stem Cell Ther. 2021.
Modi D, Surapaneni M, Kim S, Ayash L, Alavi A, Ratanatharathorn V, Deol A, Uberti JP. Allogeneic stem cell transplant provides durable response in peripheral T-cell lymphoma. Leuk Res. 2019;83:106171.
Modi D, Alkassis S, Kim S, Kin A, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission. Leuk Lymphoma. 2023:1-10.